MYCOPHENOLATE MOFETIL tablet, film coated MYCOPHENOLATE MOFETIL capsule

Land: USA

Språk: engelsk

Kilde: NLM (National Library of Medicine)

Aktiv ingrediens:

MYCOPHENOLATE MOFETIL (UNII: 9242ECW6R0) (MYCOPHENOLIC ACID - UNII:HU9DX48N0T)

Tilgjengelig fra:

Strides Pharma Science Limited

INN (International Name):

MYCOPHENOLATE MOFETIL

Sammensetning:

MYCOPHENOLATE MOFETIL 500 mg

Administreringsrute:

ORAL

Resept typen:

PRESCRIPTION DRUG

Indikasjoner:

Mycophenolate mofetil (MMF) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies (14.1)] , heart [see Clinical Studies (14.2)] or liver transplants [see Clinical Studies (14.3)] , in combination with other immunosuppressants. Allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (MMF), mycophenolic acid (MPA) or any component of the drug product. Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment. To report a pregnancy or obtain information about the registry, visit www.mycophenolateREMS.com or call 1-800-617-8191. Risk Summary Use of mycophenolate mofetil (MMF) during pregnancy is associated with

Produkt oppsummering:

Mycophenolate mofetil (MMF) has demonstrated teratogenic effects in humans [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)] . Mycophenolate mofetil tablets should not be crushed and mycophenolate mofetil capsules should not be opened or crushed. Wearing disposable gloves is recommended during reconstitution and when wiping the outer surface of the bottle/cap and the table after reconstitution. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in mycophenolate mofetil capsules [see Dosage and Administration (2.6)]. Follow applicable special handling and disposal procedures1 .

Autorisasjon status:

Abbreviated New Drug Application

Informasjon til brukeren

MYCOPHENOLATE MOFETIL - MYCOPHENOLATE MOFETIL CAPSULE
Strides Pharma Science Limited
----------
MEDICATION GUIDE
Mycophenolate Mofetil Capsules, USP and
Mycophenolate Mofetil Tablets, USP
(mye'' koe fen' oh late moe' fe til)
Read the Medication Guide that comes with mycophenolate mofetil
tablets and capsules before you start
taking it and each time you refill your prescription. There may be new
information. This Medication Guide
does not take the place of talking with your doctor about your medical
condition or treatment.
What is the most important information I should know about
mycophenolate mofetil?
Mycophenolate mofetil can cause serious side effects, including:
Increased risk of loss of a pregnancy (miscarriage) and higher risk of
birth defects. Females who take
mycophenolate mofetil during pregnancy have a higher risk of
miscarriage during the first 3 months (first
trimester), and a higher risk that their baby will be born with birth
defects.
•
If you are a female who can become pregnant, your doctor must talk
with you about acceptable birth
control methods (contraceptive counseling) to use while taking
mycophenolate mofetil. You should
have 1 pregnancy test immediately before starting mycophenolate
mofetil and another pregnancy
test 8 to 10 days later. Pregnancy tests should be repeated during
routine follow-up visits with your
doctor. Talk to your doctor about the results of all of your pregnancy
tests.
You must use acceptable birth control during your entire mycophenolate
mofetil treatment and for 6 weeks
after stopping mycophenolate mofetil, unless at any time you choose to
avoid sexual intercourse
(abstinence) with a man completely. Mycophenolate mofetil decreases
blood levels of the hormones in birth
control pills that you take by mouth. Birth control pills may not work
as well while you take
mycophenolate mofetil, and you could become pregnant. If you take
birth control pills while using
mycophenolate mofetil you must also use another form of birth control.
Talk to your doctor about other
birth con

Preparatomtale

MYCOPHENOLATE MOFETIL - MYCOPHENOLATE MOFETIL TABLET, FILM COATED
MYCOPHENOLATE MOFETIL - MYCOPHENOLATE MOFETIL CAPSULE
STRIDES PHARMA SCIENCE LIMITED
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
MYCOPHENOLATE
MOFETIL CAPSULES AND MYCOPHENOLATE MOFETIL TABLETS SAFELY AND
EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR MYCOPHENOLATE MOFETIL CAPSULES AND
MYCOPHENOLATE
MOFETIL TABLETS.
MYCOPHENOLATE MOFETIL CAPSULES, FOR ORAL USE
MYCOPHENOLATE MOFETIL TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1995
WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES AND SERIOUS INFECTIONS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING_
USE DURING PREGNANCY IS ASSOCIATED WITH INCREASED RISKS OF FIRST
TRIMESTER PREGNANCY
LOSS AND CONGENITAL MALFORMATIONS. AVOID IF SAFER TREATMENT OPTIONS
ARE AVAILABLE.
FEMALES OF REPRODUCTIVE POTENTIAL MUST BE COUNSELED REGARDING
PREGNANCY
PREVENTION AND PLANNING _[SEE WARNINGS AND PRECAUTIONS (5.1)]._
INCREASED RISK OF DEVELOPMENT OF LYMPHOMA AND OTHER MALIGNANCIES,
PARTICULARLY OF
THE SKIN _[SEE WARNINGS AND PRECAUTIONS (5.2)]_ .
INCREASED SUSCEPTIBILITY TO INFECTIONS, INCLUDING OPPORTUNISTIC
INFECTIONS AND SEVERE
INFECTIONS WITH FATAL OUTCOMES _[SEE WARNINGS AND PRECAUTIONS (5.3)]._
RECENT MAJOR CHANGES
Indications and Usage, Pediatric Heart or Liver Transplants (1)
…………………………………………
6/2022
Dosage and Administration, Dosage Recommendations for Heart Transplant
Patients
(2.3)
…………………………………………………………………………………………………………….
6/2022
Dosage and Administration, Dosage Recommendations for Liver Transplant
Patients (2.4)
……………………………………………………………………………………………………………..
6/2022
Warnings and Precautions, Serious Infections (5.3)
……………………………………………………...
10/2021
Warnings and Precautions, Acute Inflammatory Syndr